Travere Therapeutics Inc. (TVTX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform
Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI's strong growth in IgAN and recent FSGS approval. TVTX's premium valuation is justified by rapid revenue expansion, significant operating leverage, and strategic pipeline moves like the civorebrutinib acquisition. FILSPARI's unique positioning and first-mover advantage in FSGS, alongside a simplified REMS, support continued market penetration despite a competitive IgAN landscape.
Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript
Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript
Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript
Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.47 per share a year ago.
Travere Therapeutics: Still Undervalued Post FSGS Approval
Travere Therapeutics is rated a BUY following Filspari's landmark FDA approval for FSGS, making it the only approved therapy for this indication. TVTX remains undervalued, with projected peak sales of $2.2–3B across FSGS and IgAN, and a forward PE of 8.84 versus a sector median of ~18. Filspari's commercial launch benefits from cross-selling synergies with IgAN, leveraging existing infrastructure to accelerate FSGS market penetration and reduce costs.
Travere Therapeutics: Re-Rating Potential As Filspari Wins Full Approval
Travere Therapeutics secured full FDA approval for Filspari in FSGS, expanding its rare kidney disease franchise and driving a 37% stock surge. The FSGS approval increases TVTX's U.S. addressable market by 30,000 patients, supporting a multi-year revenue and earnings inflection not yet fully reflected in estimates. Filspari's unique, non-immunosuppressive mechanism and first-mover status in FSGS position TVTX for premium pricing and significant volume-driven revenue growth.
TVTX Stock Soars on FDA Nod for Filspari in Second Kidney Indication
Travere Therapeutics stock jumps 37% after the FDA expands Filspari's use to a second rare kidney disease, boosting its market reach and treatment potential.
Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript
Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript
US FDA expands approval for Travere Therapeutics' drug for rare kidney disease
The U.S. Food and Drug Administration has approved the expanded use of Travere Therapeutics' drug to treat a rare kidney disorder, the company said on Monday.
